Key Takeaways
- The Fifth Circuit upheld FDA’s 2021 PMTA rule on Feb. 26, 2026.
- The court said FDA made a reasonable, good-faith effort to meet the RFA’s procedural requirements.
- The panel found the 2016 “deeming rule” cost assessment supported FDA’s certification on small-entity impact.
- The court said PMTA disclosure of health-risk investigation information is mandated by the Tobacco Control Act.
- The case is Kealani Distribution LLC et al. v. Food & Drug Administration et al., No. 25-40135.
2Firsts, February 27, 2026
According to Law360, the U.S. Court of Appeals for the Fifth Circuit affirmed that the U.S. Food and Drug Administration complied with the law when it issued a 2021 rule requiring companies seeking premarket authorization of new tobacco products to investigate and disclose information about the product’s health effects.
In a published opinion, the three-judge panel held that FDA met its obligations under the Regulatory Flexibility Act (RFA) to certify that the 2021 final regulation would not have a significant economic impact on a substantial number of small entities. The unanimous decision concluded that FDA made a reasonable, good-faith effort to comply with the RFA’s procedural requirements and affirmed a trial court’s February 2025 grant of summary judgment to the agency.
The plaintiffs — a group of e-liquid manufacturers and the trade group United States Vaping Association — argued that the 2021 rule improperly relied on an economic analysis conducted for a prior 2016 “deeming rule” governing premarket tobacco product authorizations. The court found the 2016 cost assessment provided an adequate factual basis for FDA’s certification regarding the 2021 final PMTA rule.
The plaintiffs also contended FDA failed to consider less onerous requirements. The Fifth Circuit rejected that argument, finding that several requirements described as burdensome — including the obligation that applicants submit information about the potential dangers and benefits of their products — were mandated by the Tobacco Control Act. The court held that the requirement for an applicant to include all known information concerning health-risk investigations in a PMTA is imposed by statute, and FDA cannot dispense with a congressional mandate through regulation.
The lawsuit, filed in October 2022, alleged that many in the industry spent significant money attempting to comply with what they called FDA’s burdensome requirements, only to have applications rejected. The court’s decision left intact the challenged rule.
The case is Kealani Distribution LLC et al. v. Food & Drug Administration et al., case number 25-40135, in the U.S. Court of Appeals for the Fifth Circuit.
Image Source： Law360
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
